Fox Run Management L.L.C. Buys New Holdings in Orthofix Medical Inc. (NASDAQ:OFIX)

Fox Run Management L.L.C. bought a new stake in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 18,748 shares of the medical device company's stock, valued at approximately $327,000.

A number of other institutional investors and hedge funds have also made changes to their positions in OFIX. Victory Capital Management Inc. grew its stake in shares of Orthofix Medical by 3.3% in the third quarter. Victory Capital Management Inc. now owns 64,807 shares of the medical device company's stock worth $1,012,000 after acquiring an additional 2,074 shares during the last quarter. Quest Partners LLC grew its position in Orthofix Medical by 187.1% during the 3rd quarter. Quest Partners LLC now owns 13,908 shares of the medical device company's stock valued at $217,000 after purchasing an additional 9,063 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Orthofix Medical by 17.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 34,632 shares of the medical device company's stock valued at $541,000 after purchasing an additional 5,039 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Orthofix Medical by 14.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 324,807 shares of the medical device company's stock worth $5,073,000 after buying an additional 39,901 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Orthofix Medical by 37.4% in the third quarter. BNP Paribas Financial Markets now owns 34,758 shares of the medical device company's stock worth $543,000 after buying an additional 9,456 shares during the last quarter. Institutional investors own 89.76% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on OFIX. StockNews.com raised shares of Orthofix Medical from a "hold" rating to a "buy" rating in a research report on Tuesday, February 25th. Canaccord Genuity Group reissued a "buy" rating and issued a $24.00 target price on shares of Orthofix Medical in a report on Wednesday, February 26th. Finally, Roth Mkm reissued a "buy" rating and issued a $22.00 target price on shares of Orthofix Medical in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $23.33.

Insiders Place Their Bets

In other Orthofix Medical news, insider Lucas Vitale sold 4,287 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $16.60, for a total value of $71,164.20. Following the completion of the sale, the insider now owns 135,317 shares in the company, valued at $2,246,262.20. This represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Massimo Calafiore sold 9,203 shares of Orthofix Medical stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $17.14, for a total value of $157,739.42. Following the transaction, the chief executive officer now directly owns 124,151 shares in the company, valued at approximately $2,127,948.14. The trade was a 6.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,999 shares of company stock worth $512,497. Company insiders own 2.60% of the company's stock.

Orthofix Medical Stock Performance

Shares of OFIX stock traded down $0.10 on Friday, reaching $16.06. The stock had a trading volume of 150,950 shares, compared to its average volume of 258,356. The stock has a market cap of $626.69 million, a P/E ratio of -5.13 and a beta of 1.06. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. The company has a 50 day simple moving average of $17.63 and a 200 day simple moving average of $17.37. Orthofix Medical Inc. has a 1 year low of $12.08 and a 1 year high of $20.73.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.